www.arborpharma.com
CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia,
CryoLife is a leader in the manufacturing, processing, and distribution
of implantable living tissues and medical devices used in cardiac
surgical procedures. CryoLife markets and sells products in more than 80
countries worldwide. CryoLife is being honored for its January 2016
acquisition of On-X Life Technologies Holdings, an Austin, Texas-based,
privately held mechanical heart valve company. For additional
information about CryoLife, visit www.cryolife.com.
Private Financing
Axion
BioSystems, Inc.
Axion BioSystems, a life science company
located in Atlanta, GA, has developed the industry's first
high-throughput microelectrode array (MEA) product line. MEAs are used
for the in-vitro investigation of networks of electrically active
cells (e.g. neurons, cardiac cells, muscle cells etc.) for screening
compounds, chemicals, toxins etc. When combined with modern cell culture
technologies, Axion's platform allows scientists to model human
heart-beats and brain activity in a dish. Axion's products are used by
pharmaceutical and biotech companies, governmental agencies, and
universities for drug safety, drug discovery, and disease modeling
assays. In May 2016, Axion Biosystems closed a $6 million equity
financing round which included funds from the Georgia Research Alliance
Venture Fund. Funds will be used to grow Axion's core life science
instrumentation product line. For more information, visit https://www.axionbiosystems.com/.
Initial Public Offering & Private Financing
Clearside
Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in
Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical
company that envisions a world without blindness. Clearside relentlessly
pursues transformative, elegant, precise solutions to restore and
preserve vision. Clearside is developing advanced clinical and
pre-clinical candidates using a proprietary treatment approach offering
unprecedented access to the back of the eye through the suprachoroidal
space (SCS (News - Alert)™). This offers potentially meaningful treatment benefit to
patients suffering from sight threatening diseases like uveitis, retinal
vein occlusion, diabetic macular edema and wet age-related macular
degeneration. Clearside is being honored for the December 2015 closing
of a $20 million Series C financing and the June 2016 announcement of
the pricing of its initial public offering of 7,200,000 shares of its
common stock at a public offering price of $7.00 per share. For more
information, visit http://clearsidebio.com/.
Public Financing
Alimera
Sciences, Inc.
Alimera Sciences, a pharmaceutical company
located in Atlanta, Georgia that focuses on diseases affecting the back
of the eye, or retina, closed on an underwritten public offering of its
common stock in August of 2016 for gross proceeds of $26.5 million. For
more information, visit http://www.alimerasciences.com/.
For a list of past Georgia Bio award recipients, click
here.
Georgia Bio (www.gabio.org)
is the state's life science industry association whose members include
pharmaceutical, biotechnology and medical device companies, medical
centers, universities and research institutes, government groups and
other business organizations involved in the development of life
sciences related products and services.
Note to Editors: Credentialed
members of the news media are invited to attend. Registration is
complimentary. Please contact Maria Thacker (404-920-2042; [email protected]).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170118005258/en/
[ Back To TMCnet.com's Homepage ]